Compared to an identical anti-PD-1 antibody that lacked FcγR binding, the S228P-mutated antibody displayed a reduced anti-tumor effect in vivo, highlighting the potential role of FcγR-expressing myeloid cells in the negative regulation of ICIs (131). The gene discussed is FCGR2A; the disease is neoplasm.